Cambodia vs Republic of Moldova: Average cost of multi drug-resistant tuberculosis treatment
Cambodia
850 constant 2022 US$
in 2024
Republic of Moldova
824 constant 2022 US$
in 2024
Cambodia rank
58th
Republic of Moldova rank
60th
Average cost of multi drug-resistant tuberculosis treatment over time
- Cambodia
- Republic of Moldova
How they compare
Cambodia currently reports 850 constant 2022 US$ against 824 constant 2022 US$ in Republic of Moldova, a difference of 26 constant 2022 US$.
The two have swapped places 3 times across 7 shared years of data; in 2017 it was Republic of Moldova ahead.
Cambodia ranks 58th and Republic of Moldova ranks 60th of 92 countries.
Across the 2 decades both report, Cambodia averaged higher in 1 and Republic of Moldova in 1.
Head to head by decade
| Decade | Cambodia | Republic of Moldova | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,247 constant 2022 US$ | 2,572 constant 2022 US$ | 325 constant 2022 US$ | Republic of Moldova |
| 2020s | 1,688 constant 2022 US$ | 1,306 constant 2022 US$ | 381.75 constant 2022 US$ | Cambodia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Cambodia or Republic of Moldova?
- Cambodia, at 850 constant 2022 US$ against 824 constant 2022 US$ in Republic of Moldova as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Cambodia and Republic of Moldova?
- 26 constant 2022 US$, with Cambodia ahead.
- How many years of comparable data are there for Cambodia and Republic of Moldova?
- 7 years are reported by both, from 2017 to 2024.
- How do Cambodia and Republic of Moldova rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Cambodia ranks 58th and Republic of Moldova ranks 60th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.